<DOC>
	<DOCNO>NCT01610206</DOCNO>
	<brief_summary>Ovarian cancer lead cause gynecologic cancer death , fifth common cause cancer death woman . While approximately 75 % patient epithelial ovarian cancer respond first-line chemotherapy platinum paclitaxel , patient advance stage epithelial ovarian cancer experience disease recurrence . Pazopanib novel agent recently approve treatment subject advance renal cell carcinoma ( RCC ) , preclinical study suggest may effective cancer ovarian cancer . Therefore , purpose study test efficacy safety novel agent , pazopanib , adjunct standard treatment , gemcitabine , recurrent persistent ovarian cancer . This open label study subject randomize 1:1 receive 4 cycle either gemcitabine , gemcitabine pazopanib . Gemcitabine administer IV infusion weekly day 1 8 21 day cycle . Subjects randomize receive pazopanib take 800 mg daily 21 day cycle . All subject monitor toxicity indicator safety ( labs , physical exam , vitals ) interval throughout treatment cycle . Subjects follow 5 year follow conclusion treatment evaluate efficacy . The primary endpoint study progression free survival overall survival , assess three year .</brief_summary>
	<brief_title>A Randomized Study Safety Efficacy Pazopanib Gemcitabine Persistent Relapsed Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Must least 18 year old Must measurable detectable ovarian , fallopian primary peritoneal cancer Must treat previously carboplatin , cisplatin another organoplatinum compound Women pregnant nursing History congenital long QT syndrome Active bleeding risk bleed disorder Other significant medical condition history medical condition may put patient risk</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>recurrent</keyword>
	<keyword>persistent</keyword>
</DOC>